How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Chang, Ying-Jun; Luznik, Leo; Fuchs, Ephraim J.; Huang, Xiao-Jun

doi:10.1186/s13045-016-0265-2

Journal of Hematology & Oncology

Table 1 Recent informative trials and results of T-cell-replete haploidentical stem cell transplantation

From: How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Reference, year, ref, and median age	Patients (No.)	Diagnosis	Graft	ANC median (range)	PLT median (range)	GVHD		TRM	Relapse	LFS	OS
Reference, year, ref, and median age	Patients (No.)	Diagnosis	Graft	ANC median (range)	PLT median (range)	Acute II–IV	Chronic	TRM	Relapse	LFS	OS
Unmanipulated haplo-SCT with ATG
Di Bartolomeo P, et al. [57] (37)	80	HM	G-BM	21 (12–38)	28 (14–185)	24 %	17 % at 2 yr	36 % at 3 yr	21 % at 1 yr	38 % at 3 yr	45 % at 3 yr
Wang Y, et al. [10] (25)	1210	HM	G-BM + G-PB	13 (8–49)	16 (5–100)	40 %	50 %	17 % at 3 yr	17 % at 3 yr	67 % at 3 yr	70 % at 3 yr
Luo Y, et al. [14] (25)	99	HM	G-PB	12 (8–24)	15 (6–53)	42.4 %	41.4 % at 2 yr	30.5 % at 5 yr	14.2 % at 5 yr	58.3 % at 5 yr	60.8 % at 5 yr
Gao L, et al. [66] (25.4)	26	SAA	G-PB + G-BM	13 (11–19)	13 (10–21)	8.0 %	40 %	15.4 % at 2 yr	NA	NA	84.6 % at 2 yr
Peccatori J, et al. [19] (48)	121	HM	G-PB	17 (11–61)	19 (7–154)	35 %	47 % at 2 yr	31 % at 3 yr	48 % at 3 yr	20 % at 3 yr	25 % at 3 yr
Shin SH, et al. [29] (48)	60	MDS	G-PB	12 (8–23)	15 (6–132)	36.7 %	48.3 %	23.3 % at 2 yr	34.8 % at 2 yr	41.9 % at 2 yr	46.6 % at 2 yr
Yahng SA, et al. [120] (41)	80	AML	G-PB	11	10	47.5 %	45 %	12.2 % at 2 yr	26.6 % at 2 yr	61.1 % at 2 yr	66 % at 2 yr
Lin X, et al. [78] (23)	105	HM	G-PB	14 (10–25)	16 (9–38)	21.9 %	24.1 % at 2 yr	30.5 % at 3 yr	21.9 % at 3 yr	41.1 % at 3 yr	50.6 % at 3 yr
TCR haplo-SCT with PT/Cy
Raiola AM, et al. [38] (45)	92	HM	SS-BM (92)	18 (11–32)	32 (5–83)	14 %	15 %	18 % at 1000 days	35 %	43 % at 4 yr	52 % at 4 yr
McCurdy SR, et al. [36] (55)	372	HM	SS-BM	90 %^a	88 %^b	32 % at 6 m	13 % at 2 yr	11 % at 1 yr	46 % at 3 yr	40 % at 3 yr	50 % at 3 yr
Bacigalupo A, et al. [37] (47)	148	HM	SS-BM	17 (13–32)	NA	18 %	20 % at 2 yr	14 % at 4 yr	27 % at 4 yr	NA	77 % for CR1 49 % for CR2 38 % for AD
Solomon SR, et al. [61] (46)	30	HM	G-PB	16 (NA)	25 (NA)	43 %	56 %	3 % at 2 yr	24 % at 2 yr	73 % at 2 yr	78 % at 2 yr
Cieri N, et al. [64] (55)	40	HM	G-PB	18 (13–45)	16 (9–100)	15 %	20 % at 1 yr	17 % at 1 yr	35 % at 1 yr	48 % at 1 yr	56 % at 1 yr
Esteves I, et al. [65] (17)	16	SAA	SS-BM (13) G-PB (3)	19 (16–29)	21 (20–29)	13 %	20 %	32.9 % at 1 yr	NA	NA	67.1 % at 1 yr
Ciurea SO, et al. [62] (NA)	104^c	AML	SS-BM (85) G-PB (19)	90 %	88 %	16 %	30 % at 3 yr	14 % at 3 yr	44 % at 3 yr	NA	45 % at 3 yr
Ciurea SO, et al. [62] (NA)	88^d	AML	SS-BM (77) G-PB (11)	93 %	88 %	19 %	34 % at 3 yr	9 % at 3 yr	58 % at 3 yr	NA	46 % at 3 yr
Kasamon YL, et al. [59] (61)	271	HM	SS-BM	88–93 %	84–89 %	33 % at 6 m	12 % at 1 yr	10 % at 1 yr	46 % at 3 yr	37 % at 3 yr	46 % at 3 yr

Published between 2013 and 2015
Ref reference, Pts patients, No. number, ANC absolute neutrophil count, PLT platelet, GVHD graft-versus-host disease, TRM transplant-related mortality, LFS leukemia-free survival, OS overall survival, haplo-SCT haploidentical stem cell transplantation, ATG anti-thymocyte globulin, HM hematological malignancies, G-BM granulocyte colony-stimulating factor (G-CSF)-primed bone marrow, yr year, G-PB G-CSF-mobilized peripheral blood stem cell grafts, UCB umbilical cord blood, NA not available, AL acute leukemia, SAA severe aplastic anemia, MDS myelodysplastic syndrome, AML acute myeloid leukemia, PT/Cy posttransplant cyclophosphamide, SS-BM steady-state bone marrow, m months, AD advanced disease
^aIndicates the probability of neutrophil recovery by day 30
^bIndicates the probability of platelet recovery ≥20,000/μL by day 60
^cIndicates that patients received myeloablative conditioning regimens
^dIndicates that patients received reduced intensity conditioning regimens

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com